KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Other Non-Current Liabilities readings, the most recent being $3.7 billion for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities fell 7.53% to $3.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 billion, a 7.53% decrease, with the full-year FY2025 number at $3.8 billion, down 5.46% from a year prior.
  • Other Non-Current Liabilities hit $3.7 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $3.8 billion in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 billion in Q2 2024 to a low of $3.3 billion in Q1 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $4.0 billion (2023), compared with a mean of $3.9 billion.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 75.17% in 2022 and later dropped 15.65% in 2025.
  • Teva Pharmaceutical Industries' Other Non-Current Liabilities stood at $3.9 billion in 2022, then grew by 1.88% to $4.0 billion in 2023, then increased by 0.22% to $4.0 billion in 2024, then fell by 5.46% to $3.8 billion in 2025, then dropped by 2.6% to $3.7 billion in 2026.
  • The last three reported values for Other Non-Current Liabilities were $3.7 billion (Q1 2026), $3.8 billion (Q4 2025), and $3.7 billion (Q3 2025) per Business Quant data.